12/07/2018 23:02:49

Syneos Health Schedules Second Quarter 2018 Earnings Call for Thursday, August 2, 2018

RALEIGH, N.C., July 12, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO (Contract Commercial Organization), will release its second quarter 2018 financial results on Thursday, August 2, 2018, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 2556819.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on August 2. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 2556819.

About Syneos Health

Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Investor Relations Contact:                             

Ronnie Speight                                                    

Vice President, Investor Relations                       

+1 919 745 2745                                                  

investor.relations@syneoshealth.com                 

Press/Media Contact:

Danielle DeForge

Executive Director, External Communications

+1 781 425 2624

danielle.deforge@syneoshealth.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Sep
 
Jeg har været med som skribent her på EI siden 2012 og jeg har haft mange gode øjeblikke ved at være..
62
20 Sep
VWS
Vestas aktien fylder en del i min portefølje, hvorfor jeg følger den tæt. Jeg var dog selv tidligere..
32
16 Sep
OMXC25
Putin kan lukke samtlige banker i Europa blot ved at sende nogle penge igennem dem, og bagefter lækk..
29
18 Sep
BIOPOR
BioPorto - InvestorDagen 18.september 2018 Jeg deltog til præsentationen af BioPorto ved CFO Ole ..
24
20 Sep
 
Danmark forærer 12mia kr væk til svindlere - med hjælp fra et par fordrukne ansatte i skat. Så stort..
20
18 Sep
PNDORA
.....lyder ikke for klogt. Nu har vi været under pres fra shortere i lang tid i Pandora som fik bank..
20
20 Sep
DANSKE
Erhversministeren mener at hvidvaskskandalen er "en af de største skandaler i danmarkshistorien" og ..
16
15 Sep
DANSKE
...og jeg kan supplere, man skal ikke tro på mennesker der er maniske eller totalt besatte af en giv..
16
16 Sep
BAVA
Bava var sat op til en næsten perfekt IHS, der ville sende den op i ca. 225.   Men så kommer der lig..
14
20 Sep
PNDORA
Til jer der foelger Pandopra smider jeg lige et link til en god Forbesartikel der giver et godt indt..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)
2
The observation status for Skånska Energi AB is updated (344/18)
3
Carlyle Announces Pricing the Tender Offer for up to $250 Million 3.875% Senior Notes due 2023
4
AMG Advanced Metallurgical Group N.V. Completes Multi-Year Agreement for 100% Renewable Energy Contract for UK Operations
5
Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 September 2018 05:06:42
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB2 - 2018-09-22 06:06:42 - 2018-09-22 05:06:42 - 1000 - Website: OKAY